CSPC Pharmaceutical Group Limited

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 12:08:56 21/01/2026 +04			5-day change	1st Jan Change
9.890 ^HKD	+1.64%		+1.12%	+17.32%

01-15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01-15	CSPC Innovation Pharmaceutical Warns of Swing to 2025 Loss	MT

CSPC Pharma Gets China Nod to Market New Indication of Pancreatic Cancer Drug

Published on 12/12/2025 at 03:08 pm +04

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about CSPC Pharmaceutical Group Limited

01-15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
01-15	CSPC Innovation Pharmaceutical Warns of Swing to 2025 Loss	MT
01-15	CSPC Pharmaceutical forecasts FY net loss attributable for CSPC Innovation Pharmaceutical	RE
01-13	CSPC Pharmaceutical says SYH2072 tablets obtain U.S. FDA approval for clinical trials	RE
01-13	Cspc Pharmaceutical Group Limited Announces Potent Aldosterone Synthase Inhibitor (Syh2072 Tablets) Obtains Clinical Trial Approval in the U.S	CI
01-12	CSPC Pharma's Marketing Application for Glycemic Control Drug Accepted in China	MT
01-12	CSPC Pharmaceutical says NMPA accepts marketing authorisation application for Prusogliptin, Metformin	RE
01-12	Cspc Pharmaceutical Group Limited Announces the Marketing Authorisation Application for Prusogliptin and Metformin Extended-Release Tablets	CI
01-02	CSPC Pharmaceutical says nintedanib esilate powder approved for clinical trials in China	RE
01-02	CSPC Pharmaceutical Group Limited Announces Nintedanib Esilate Powder for Inhalation Obtains Clinical Trial Approval in China	CI
01-02	CSPC Pharma Gets China Nod for Pulmonary Fibrosis Drug Trial	MT
12-29	Novo and Lilly cut prices of weight-loss drugs in China	RE
12-29	CSPC Pharmaceutical says potent aldosterone synthase inhibitor obtains clinical trial approval	RE
12-29	CSPC Pharma Gets China Nod for Multiple Drug Trials	MT
12-29	CSPC Pharmaceutical says Prusogliptin, Dapagliflozin and Metformin extended-release tablets get clinical trial approval in China	RE
12-29	CSPC Pharmaceutical Group Limited Announces Potent Aldosterone Synthase Inhibitor (SYH2072 Tablets) Obtains Clinical Trial Approval in China	CI
12-29	CSPC Pharmaceutical says GLP-1/GIP receptor dual-biased agonist polypeptide injection gets clinical trial approval in China	RE
12-29	CSPC Pharmaceutical Group Limited Announces Prusogliptin, Dapagliflozin and Metformin Extended-Release Tablets Obtain Clinical Trial Approval in China	CI
12-29	CSPC Pharmaceutical Group Limited Announces GLP-1/GIP Receptor Dual-Biased Agonist Polypeptide Injection (SYH2069 Injection) Obtains Clinical Trial Approval in China	CI
12-23	CSPC Pharma Gets China Nod for Multiple Myeloma Drug Trial	MT
12-23	Tech Caution, Yen Outlook Limit Asian Stock Markets	MT
12-23	CSPC Pharmaceutical announces approval for daratumumab injection in China	RE
12-23	CSPC Pharmaceutical Group Limited Announces Daratumumab Injection Obtains Clinical Trial Approval in China	CI
12-19	CSPC Pharmaceutical says Zhang Cuilong steps down as vice-chairman and CEO	RE
12-19	CSPC Pharmaceutical says SYH2085 tablets obtain clinical trial approval in China	RE

Chart CSPC Pharmaceutical Group Limited

Duration

Period

1093: Dynamic Chart

CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Companyâs product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.

Employees

19,266

Sector

Pharmaceuticals

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company